STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03548935
Completed
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants taking "dummy" medicine. In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what you can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which tre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2021
Locations: Novo Nordisk Investigational Site, Anniston, Alabama +127 locations
Conditions: Metabolism and Nutrition Disorder, Overweight or Obesity
Register for Updates
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
NCT02970942
Completed
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/15/2021
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +157 locations
Conditions: Hepatobiliary Disorders, Non-alcoholic Steatohepatitis
Register for Updates
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
NCT03552757
Completed
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the study medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what else the participant can do to lose weight. Overweight and obesity is associated with an increased risk... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2021
Locations: Novo Nordisk Investigational Site, Buena Park, California +146 locations
Conditions: Obesity, Overweight
Register for Updates
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
NCT03457012
Completed
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about the health and the diabetes treatment. Participants will complete these during the normally scheduled visits with the study doctor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2021
Locations: Novo Nordisk Investigational Site, Cambridge, Ontario
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
NCT03086330
Completed
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose co-transporter-2 inhibitor (SGLT-2i) monotherapy or in combination with either metformin or sulfonylurea on glycaemic control after 30 weeks of treatment in subjects with type 2 diabetes. Subjects will remain on their pre-trial medication.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2021
Locations: Novo Nordisk Investigational Site, Andalusia, Alabama +71 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
NCT01923181
Completed
This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2021
Locations: Novo Nordisk Investigational Site, Tucson, Arizona +102 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
NCT02453711
Completed
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2020
Locations: Novo Nordisk Investigational Site, Anaheim, California +73 locations
Conditions: Metabolism and Nutrition Disorder, Obesity
Register for Updates
Real-world Health Outcomes in Canadian Patients Using Semaglutide
NCT04175665
Completed
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are an injectable, non-insulin therapy for patients with type 2 diabetes (T2D). Semaglutide (Ozempic®) is the newest GLP-1 RA to become available in Canada in 2018, and is administered subcutaneously once-weekly. In clinical trials, semaglutide has been superior to placebo and other antihyperglycemic agents in HbA1c reduction and body weight loss. However, there is little real-world evidence available on the effectiveness of semaglutide in rea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2020
Locations: LMC Diabetes & Endocrinology, Toronto, Ontario
Conditions: Type 2 Diabetes
Register for Updates
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
NCT03021187
Completed
This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 Diabetes Mellitus treated with insulin. All subjects should continue their pre-trial insulin therapy (basal, basal-bolus or premixed regimen including combinations of soluble insulins) throughout the trial. Subjects treated with metformin in addition to insulin treatment must continue their metformin treatment throughout the entire trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2020
Locations: Novo Nordisk Investigational Site, Anniston, Alabama +118 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
NCT03136484
Completed
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) on a background treatment of metformin
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2020
Locations: Novo Nordisk Investigational Site, Anaheim, California +118 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
NCT02461589
Completed
This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2019
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +149 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
NCT01720446
Completed
This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopp... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/20/2019
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +252 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates